Background. Asymptomatic bacteriuria (ASB) is common in patients admitted to inpatient rehabilitation (IPR) units. Current guidelines recommend against routine urine testing in asymptomatic patients, including patients with spinal cord injuries (SCI). Screening for urinary tract infections (UTI) is prompted by subjective observations that may not relate to infection; however, a positive urine screen frequently prompts antimicrobial prescribing even in the absence of symptoms.
Methods. A retrospective case control study was conducted at a universityaffiliated academic medical center with a 76-bed IPR unit. 181 IPR patients hospitalized between August 2013 and October 2013 were randomly selected. The documented reasons for urine testing and results, antibiotic use, demographic information, comorbidities, and urinary catheter data were collected. SAS V9.3 was used to analyze the data. The primary objective was to determine patient factors that prompted screening and treatment and to document specific UTI symptoms. A secondary objective was to describe appropriateness of antimicrobial use.
Results. 104 patients had orders for urinalysis and/or culture. Only 17 patients (16.3%) who were screened had specific UTI symptoms as defined by the National Health Safety Network (NHSN). Among the 61 patients who were ordered antibiotics, 38 patients had ASB (62.3%). Neurogenic bladder in SCI patients is a known risk factor for UTI. Of those screened in our study, 36 patients (35%) had documented neurogenic bladder, while 10 (13%) patients without screening had neurogenic bladder (OR = 3.4, 95% CI = 1.6-7.4, p = 0.002). Results from a multivariate analysis determined the following factors associated with urine screening. Conclusion. The primary use of antimicrobial agents on the IPR units at our institution is for the treatment of ASB. The practice of routine urine screening for asymptomatic patients should be revisited. This project identifies an opportunity for targeted antimicrobial stewardship efforts.
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